NCI-H1975-EGFR-KO-EGFR-L858R-C797S-Flag Cell Line

Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes one of the four members of ErbB family of tyrosine kinase receptors. The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as fos and jun. EGFR is abnormally activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with the development of variety of human cancers. EGFR mutations, including L858R (exon 21) and C797S (exon 20), drive non-small cell lung cancer (NSCLC) progression. L858R is a common activating mutation sensitizing tumors to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib. However, acquired resistance frequently arises through the C797S mutation, which counters third-generation TKIs (e.g., osimertinib) and often coexists with the T790M resistance mutation.